Parsortix, a subsidary of Angle, has acheived a major milestone for its cell separation device which can capture circulating tumour cells (CTCs) in cancer patient blood.
The device capturing ability made several cancer institutes interest in such a product, which would not require regulatory approval for use for research purposes.
The target is to establish sales of the product for research purposes.
After initial discussions, it was confirmed that the medical diagnostic companies also had interest in a commercial collaboration.
The target is to obtain the US Food and Drug Administration (FDA) and CE mark certifications by mid 2013 enabling sales of product for clinical use in relation to early detection of cancer; monitoring of cancer patients during treatment; post-treatment monitoring of cancer patients in remission.
Angle founder and chief executive Andrew Newland said these findings along with discussions they have had with cancer experts reinforce their view that Parsortix’s cancer diagnostic has the potential to meet a medical requirement and offers a commercial opportunity for Angle.